Laura Boucai MD MSc
Thyroid
Associate Professor, Medicine, Endocrinology, Memorial Sloan Kettering Cancer Center, Cornell University
530 East 74th StreetNew York, NY 10021
Overview of Dr. Boucai
Laura Boucai, MD, is an endocrinologist based in New York, NY, specializing in thyroid conditions. She completed her residency in Internal Medicine at New York Presbyterian Hospital- Weill Cornell Medical College and her fellowship in Endocrinology, Diabetes, and Metabolism at Montefiore Medical Center/Albert Einstein College of Medicine. She is currently an Associate Professor at Memorial Sloan Kettering Cancer Center - Weill Cornell Medical College. Dr. Boucai has several publications, focusing mainly on thyroid cancer and thyroid dysfunction, with some of her work cited by other publications. She is also the principal investigator in a clinical trial studying the use of redifferentiation medications in the standard treatment for thyroid cancer.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Endocrinology, Diabetes, and Metabolism, 2006 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2006- New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 2003 - 2004
University of Buenos AiresClass of 2002
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2008 - 2026
NJ State Medical License 2020 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer Start of enrollment: 2023 Feb 07
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citationsRBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs.Gnana P Krishnamoorthy, Anthony R Glover, Brian R Untch, Nickole Sigcha-Coello, Bin Xu
The Journal of Experimental Medicine. 2025-05-05 - 1 citationsDecision Variables for the Use of Radioactive Iodine in Patients with Thyroid Cancer at Intermediate Risk of Recurrence.Samantha K Newman, Armando Patrizio, Laura Boucai
Cancers. 2024-09-06 - RBM10 loss induces aberrant splicing of cytoskeletal and extracellular matrix mRNAs and promotes metastatic fitness.Gnana P Krishnamoorthy, Anthony R Glover, Brian R Untch, Nickole Sigcha-Coello, Bin Xu
Biorxiv. 2024-07-10
Press Mentions
Preview of the 93rd American Thyroid Association Annual MeetingJuly 1st, 2024- Digging into the Interpretation of TSH ResultsMay 23rd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
